Merah Putih Vaccine Heading Into Pilot Phase; Clinical Trials Soon
Translator
Ricky Mohammad Nugraha
Editor
Petir Garda Bhwana
Rabu, 24 November 2021 13:30 WIB
TEMPO.CO, Jakarta - Airlangga University Surabaya Rector Mohammad Nasih said that PT Biotis Pharmaceuticals Indonesia is producing a pilot scale of the Merah Putih Vaccine using vaccine seeds produced by the campus.
He said to journalists on November 23 that “This is used to inoculate vaccine volunteers,” Antaranews reported.
Pilot scale production, he added, is a limited production vaccine batch specifically used for the three stages of clinical trials as the first clinical trial is slated for December this year on a small group of volunteers.
The clinical trials will be permitted to be conducted in parallel with each other once the permit is obtained. This means the more advanced trial can be conducted as the first clinical trial is being finalized.
“This will progress and hopefully in January 2022 the third clinical trial can be conducted. We are doing it in parallel but there will be gaps in between,” he said.
The Merah Putih vaccine is a live attenuated vaccine where a whole bacteria or virus has been weakened and is injected to people so that they create a protective immune response but do not cause disease in healthy people.
Read: Merah Putih Vaccine Targeted to Earn EUA by March 2022
ANTARA
